NasdaqGS:ZYMEBiotechs
Zymeworks (ZYME): Reassessing Valuation After FDA Zanidatamab Approval and a Sharp Share Price Rally
The recent FDA approval of zanidatamab for HER2 positive biliary tract cancer has pushed Zymeworks (ZYME) into the spotlight. Upcoming conference presentations will give investors more to consider regarding its pipeline and strategy.
See our latest analysis for Zymeworks.
That backdrop helps explain why Zymeworks' share price return has surged, with an 80.58 percent year to date gain and a 62.15 percent 1 month move. Its 3 year total shareholder return of 297.76 percent signals strong,...